{"denoms":[{"counts":[{"groupId":"BG000","value":"5"}],"units":"Participants"}],"groups":[{"description":"The patients received Volasertib 200 mg administered by Intravenous Infusion (IV) over 60 minutes on Day 1 and Day 15 of 28-day and Azacitidine 75 mg/m\\^2 administered by subcutaneous injection on days 1-7 of 28 day treatment cycle.","id":"BG000","title":"Volasertib 200 mg"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"4.6","value":"73.2"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Treated Set (TS): This patient set included all patients who were dispensed study medication and were documented to have taken at least one dose of either Volasertib or Azacitidine."}